Combination therapy approach for non-Hodgkin lymphoma (NHL)
Official title: Translation of a novel combination therapy approach for non-Hodgkin lymphoma
Funded at Mayo Clinic Rochester · NIH-11402652 · Data updated 2026-11-12
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $546,214 |
| NIH project number | 5U01CA272257-05 |
| Project ID | NIH-11402652 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with relapsed or refractory diffuse large B-cell lymphoma and owners of dogs with cDLBCL may participate in related translational studies and future trials.
✕Less likely to help
Patients without NHL or those not meeting eligibility criteria for the specific trials or translational studies may not benefit.
What this research studies
This grant supports translating a novel combo therapy for diffuse large B-cell lymphoma, aiming to overcome resistance to immunotherapies. The project uses a parallel canine model to mirror human disease and explores a vesicular stomatitis virus-based therapy combined with existing treatments. Researchers will study safety, potential toxicities, and how the tumor environment in both humans and dogs responds to therapy to inform future clinical trials. The work connects lab findings to potential patient benefits by developing strategies that could enhance durable responses in advanced NHL.
Why it matters
Potential benefit: If successful, the approach could lead to more effective treatments and longer-lasting responses for people with advanced NHL and potentially improve outcomes in canine patients as a translational model.
How similar studies have gone: Immunotherapy has shown variable success in NHL; this study explores a novel combination in a translational canine-human model, which is an innovative and exploratory approach.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Naik, Shruthi — Mayo Clinic Rochester
- Study coordinator: Naik, Shruthi
Related research
Other NIH-funded projects on the same topics.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Multi-antigen T cell therapy for relapsed NHL
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
-
Precision targeted radioactive antibody therapy for non-Hodgkin lymphoma
Researchers are developing more precise radioactive antibodies to treat people with CD20-positive non-Hodgkin lymphoma.
-
AI-designed drugs targeting a common lymphoma mutation (MYD88 L265P)
Researchers are using artificial intelligence to create and test new drugs that block a common MYD88 mutation found in many B‑cell non‑Hodgkin lymphomas to help people with these cancers.
-
New combination therapy for non-Hodgkin lymphoma
A virus-based combination treatment aims to boost the immune system to help people and companion dogs with relapsed or treatment-resistant diffuse large B-cell lymphoma.
-
New combination treatment for diffuse large B‑cell lymphoma
This project is trying a virus-based therapy together with checkpoint immunotherapy for people (and companion dogs) with relapsed diffuse large B‑cell lymphoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.